JMP Securities Has Lowered Expectations for Integra LifeSciences (NASDAQ:IART) Stock Price

Integra LifeSciences (NASDAQ:IART) had its price objective cut by JMP Securities from $35.00 to $25.00 in a research note published on Friday morning,Benzinga reports. They currently have a market outperform rating on the life sciences company’s stock.

IART has been the topic of a number of other research reports. Truist Financial dropped their price target on Integra LifeSciences from $26.00 to $19.00 and set a “hold” rating on the stock in a research report on Friday, April 11th. Argus upgraded shares of Integra LifeSciences from a “hold” rating to a “buy” rating in a research report on Monday, March 31st. JPMorgan Chase & Co. lowered their price target on shares of Integra LifeSciences from $24.00 to $12.00 and set an “underweight” rating on the stock in a research report on Tuesday. Finally, Wells Fargo & Company cut their price objective on shares of Integra LifeSciences from $25.00 to $13.00 and set an “equal weight” rating for the company in a report on Tuesday. Four equities research analysts have rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $18.63.

Integra LifeSciences Trading Down 5.0 %

NASDAQ IART opened at $12.25 on Friday. The stock has a market capitalization of $946.31 million, a price-to-earnings ratio of -136.10, a PEG ratio of 0.73 and a beta of 1.27. The business’s fifty day moving average is $18.93 and its 200-day moving average is $21.87. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73. Integra LifeSciences has a one year low of $11.60 and a one year high of $32.66.

Integra LifeSciences (NASDAQ:IART) last released its earnings results on Monday, May 5th. The life sciences company reported $0.41 earnings per share for the quarter, missing analysts’ consensus estimates of $0.43 by ($0.02). Integra LifeSciences had a negative net margin of 0.42% and a positive return on equity of 12.35%. The company had revenue of $382.65 million for the quarter, compared to the consensus estimate of $381.17 million. During the same period in the prior year, the company earned $0.55 earnings per share. The firm’s revenue was up 3.7% on a year-over-year basis. Equities research analysts predict that Integra LifeSciences will post 2.45 EPS for the current year.

Institutional Trading of Integra LifeSciences

Several institutional investors and hedge funds have recently bought and sold shares of IART. Arizona State Retirement System boosted its stake in shares of Integra LifeSciences by 4.2% in the 1st quarter. Arizona State Retirement System now owns 19,894 shares of the life sciences company’s stock valued at $437,000 after purchasing an additional 795 shares in the last quarter. Arrowstreet Capital Limited Partnership lifted its stake in Integra LifeSciences by 7.1% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 13,756 shares of the life sciences company’s stock worth $312,000 after purchasing an additional 913 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in Integra LifeSciences by 4.6% during the first quarter. Envestnet Asset Management Inc. now owns 27,527 shares of the life sciences company’s stock valued at $605,000 after buying an additional 1,204 shares during the period. Quadrant Capital Group LLC grew its stake in shares of Integra LifeSciences by 5,960.9% during the fourth quarter. Quadrant Capital Group LLC now owns 1,394 shares of the life sciences company’s stock valued at $32,000 after buying an additional 1,371 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of Integra LifeSciences by 3.9% during the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 38,466 shares of the life sciences company’s stock valued at $872,000 after buying an additional 1,437 shares during the last quarter. 84.78% of the stock is currently owned by hedge funds and other institutional investors.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.